-
公开(公告)号：US12110343B2
公开(公告)日：2024-10-08
申请号：US17684460
申请日：2022-03-02
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
-
公开(公告)号：US12103979B2
公开(公告)日：2024-10-01
申请号：US16607673
申请日：2018-04-27
申请人： AMGEN INC.
发明人： Neeraj Jagdish Agrawal , Pavan Ghattyvenkatakrishna , Sekhar Kanapuram , Christopher James Sloey
IPC分类号： A61K39/395 , A61K9/08 , A61K9/19 , A61K31/198 , A61K31/401 , A61K31/4172 , A61K38/05 , A61K47/18 , A61K47/26 , C07K5/06 , C07K16/18 , C07K16/40
CPC分类号： C07K16/40 , A61K9/08 , A61K9/19 , A61K31/198 , A61K31/401 , A61K31/4172 , A61K38/05 , A61K39/3955 , A61K39/39591 , A61K47/183 , A61K47/26 , C07K5/06 , C07K16/18
摘要： Provided herein are excipients capable of effectively reducing the viscosity of polypeptide (e.g., therapeutic polypeptide) formulations. The viscosity reducing excipients are dipeptides containing arginine at the carboxy terminus and N-acetylated serine or N-acetylated proline at the N-terminus. Glutamate-arginine is also disclosed as a viscosity-reducing dipeptide. Among the disclosed methods, methods of reducing the viscosities of such formulations are also provided.
-
13.发明公开公开(公告)号：US20240317892A1
公开(公告)日：2024-09-26
申请号：US17440299
申请日：2020-03-20
发明人： Anthony B. Cooper
IPC分类号： C07K16/40 , A61K39/00 , A61P35/00 , C12N5/0783
CPC分类号： C07K16/40 , A61K39/4611 , A61K39/4631 , A61K39/464458 , A61P35/00 , C12N5/0636 , C07K2317/24 , C12N2510/00
摘要： Anti-ADAM12 agents are provided such as anti-ADAM12 antibodies (Abs), antigen-binding Ab fragments, multi-specific Abs and antigen-binding Ab fragments, antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). Also, nucleic acid sequences and vectors are provided encoding, cells and pharmaceutical compositions comprising such anti-ADAM12 agents and methods for expanding such cells. Methods of treating, preventing, or diagnosing a disease such as cancer and methods of stimulating an immune response using such materials are also provided.
-
公开(公告)号：US20240309112A1
公开(公告)日：2024-09-19
申请号：US18546981
申请日：2022-02-18
发明人： Yuya MIYAMOTO , Koichi WADA , Yuichi IMURA , Kenji SAITO , Tomoko SAKATA , Takanari SHIGEMITSU
CPC分类号： C07K16/40 , A61P19/02 , A61P37/06 , A61K2039/505 , C07K2317/565 , C07K2317/92
摘要： Provided is an anti-PAD4 antibody or an antibody fragment thereof, wherein HCDR1 comprises an amino acid sequence of SEQ ID NO: 1, HCDR2 comprises an amino acid sequence of SEQ ID NO: 2, HCDR3 comprises an amino acid sequence of SEQ ID NO: 3, LCDR1 comprises an amino acid sequence of SEQ ID NO: 4, LCDR2 comprises an amino acid sequence of SEQ TD NO: 5, and LCDR3 comprises an amino acid sequence of SEQ ID NO: 6.
-
公开(公告)号：US20240309084A1
公开(公告)日：2024-09-19
申请号：US18272702
申请日：2022-01-18
申请人： Novartis AG
发明人： Martin ALLAN , Jeffrey BAGDANOFF , David Weninger BARNES , John BLANKENSHIP , James BRADNER , Kevin CLAIRMONT , Brian GRANDA , Guido JUNGE , Thomas SMITH , Elisabetta TRAGGIAI , Max WARNCKE
CPC分类号： C07K16/28 , A61K47/549 , A61K47/6849 , C07K16/40 , C07K2317/31 , C07K2317/62 , C07K2317/70
摘要： The present disclosure features bifunctional compounds for the degradation of extracellular targets, as well as compositions and related methods thereof.
-
公开(公告)号：US12084515B2
公开(公告)日：2024-09-10
申请号：US17345033
申请日：2021-06-11
CPC分类号： C07K16/40 , A61P27/02 , A61K9/0051 , A61K2039/505 , A61K2039/54 , C07K2317/30 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
-
17.发明授权公开(公告)号：US12084514B2
公开(公告)日：2024-09-10
申请号：US16769567
申请日：2018-12-03
发明人： Courtney W. Houchen
IPC分类号： C07K16/40 , A61K35/17 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , G01N33/50 , A61K38/00
CPC分类号： C07K16/40 , A61K35/17 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , A61K38/00 , A61K2039/505 , C12Y207/11001 , G01N33/5008 , G01N2800/52
摘要： CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.
-
公开(公告)号：US12083176B2
公开(公告)日：2024-09-10
申请号：US17560402
申请日：2021-12-23
申请人： Sanofi Biotechnology
IPC分类号： C07K16/40 , A61K39/395 , A61P3/06 , A61J1/05 , A61K31/215 , A61K31/366 , A61K31/404 , A61K31/435 , A61K31/47 , A61K31/505 , A61K39/00 , A61K45/06 , C07K14/47
CPC分类号： A61K39/3955 , A61P3/06 , C07K16/40 , A61J1/05 , A61K31/215 , A61K31/366 , A61K31/404 , A61K31/435 , A61K31/47 , A61K31/505 , A61K39/395 , A61K2039/505 , A61K2039/545 , A61K45/06 , C07K14/4703 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.
-
公开(公告)号：US12077601B2
公开(公告)日：2024-09-03
申请号：US17379739
申请日：2021-07-19
发明人： Michael Catania , Ronald L. Hayes
IPC分类号： C07K16/40 , A61B5/00 , A61B5/055 , A61B6/03 , A61B6/50 , A61P25/00 , C07K16/18 , G01N33/68 , A61B6/00
CPC分类号： C07K16/40 , A61B5/0042 , A61B5/055 , A61B6/032 , A61B6/501 , A61P25/00 , C07K16/18 , G01N33/6896 , C07K2317/20 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.
-
公开(公告)号：US12077600B2
公开(公告)日：2024-09-03
申请号：US17069349
申请日：2020-10-13
发明人： Hartmut Duefel , Alfred Engel , Frank Kroner , Thomas Meier , Sandra Rutz , Michael Schraeml , Gloria Tabares , Ulrike Kurtkaya , Boris Pinchuk , Christina Zimmermann
IPC分类号： G01N31/00 , C07K16/40 , G01N33/53 , G01N33/543
CPC分类号： C07K16/40 , G01N33/54326 , C07K2317/92
摘要： The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.
-
-
-
-
-
-
-
-
-
搜索结果
6762 条记录 (耗时 0.04 秒)
